Aligos Therapeutics upgraded by Piper Sandler with a new price target
$ALGS
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Piper Sandler upgraded Aligos Therapeutics from Neutral to Overweight and set a new price target of $3.00 from $2.00 previously